About: Computational methods to develop potential neutralizing antibody Fab region against SARS-CoV-2 as therapeutic and diagnostic tool

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Computational methods to develop potential neutralizing antibody Fab region against SARS-CoV-2 as therapeutic and diagnostic tool Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Computational methods to develop potential neutralizing antibody Fab region against SARS-CoV-2 as therapeutic and diagnostic tool
Creator	Joshi, Sunil Manikyam, Hemanth
Source	BioRxiv
abstract	SARS-CoV-2, a global pandemic originated from Wuhan city of China in the month of December 2019. There is an urgency to identify potential antibodies to neutralize the virus and also as a diagnostic tool candidate. At present palliative treatments using existing antiviral drugs are under trails to treat SARS-CoV-2.Whole Genome sequence of Wuhan market sample of SARS-CoV-2 was obtained from NCBI Gene ID MN908947.3.Spike protein sequence PDB ID 6VSB obtained from RCSB database. Spike protein sequence had shown top V gene match with IGLV1-4401, IGLV1-4702 and has VL type chain. Whole Genome sequence had shown top V gene match with IGHV1-38-401 and has VH type chain. VD chain had shown link to allele HLA-A0206 80%, HLA-A0217 80%, HLA-A2301 75%, HLA-A0203 75%, HLA-A0202 70% and HLA-A0201 55% of binding levels. Some conserved regions of spike protein had shown strong binding affinity with HLA-A-0201, HLA-A24, HLA-B-5701 and HLA-B-5703 alpha chains. Synthetic Fab construct BCR type antibody IgG (CR5840) had shown Polyspecific binding activity with spike glycoprotein when compared with available Anti-SARS antibody CR3022.Thus we propose CR5840 Fab constructed antibody as potential neutralizing antibody for SARS-CoV-2. Based on germline analysis we also propose cytotoxic T lymphocyte epitope peptide selective system as effective tool for the development of SARS-CoV-2 vaccine.
has issue date	2020-05-04(xsd:dateTime)
bibo:doi	10.1101/2020.05.02.071506
has license	biorxiv
sha1sum (hex)	4cf7e54e6432ff180901519db3b11dca0a461cd1
schema:url	https://doi.org/10.1101/2020.05.02.071506
resource representing a document's title	Computational methods to develop potential neutralizing antibody Fab region against SARS-CoV-2 as therapeutic and diagnostic tool
schema:publication	bioRxiv
resource representing a document's body	covid:4cf7e54e6432ff180901519db3b11dca0a461cd1#body_text
is schema:about of	named entity 'global' named entity 'trails' named entity 'existing' named entity 'December' named entity 'potential' named entity 'potential' named entity 'therapeutic' covid:arg/4cf7e54e6432ff180901519db3b11dca0a461cd1 named entity 'antibody' named entity 'Genome' named entity 'HLA-A' named entity 'There' named entity 'Whole' named entity 'top' named entity 'Fab' named entity 'treat' named entity 'RCSB' named entity 'chain' named entity 'Spike' named entity 'Wuhan' named entity 'binding' named entity 'match' named entity 'binding affinity' named entity 'Spike protein' named entity 'HLA' named entity 'HLA-B' named entity 'binding activity' named entity 'SARS-CoV-2' named entity 'HLA-B' named entity 'epitope' named entity 'antibody' named entity 'RCSB' named entity 'peptide' named entity 'palliative treatments' named entity 'neutralizing antibody' named entity 'compared' named entity 'clinical studies' named entity 'IgG' named entity 'viral antigens' named entity 'functional model' named entity 'COVID' named entity 'genome' named entity 'Ligands' named entity 'germline' named entity 'germline' named entity 'epitope' named entity 'antibodies' named entity 'protein structure' named entity 'COVID-19' named entity 'germline' named entity 'SARS-CoV-2' named entity 'epitopes' named entity 'database' named entity 'gene' named entity 'Fab fragments' named entity 'Phage display technology' named entity 'antibody' named entity 'antibodies' named entity 'protein ligand' named entity 'mAbs' named entity 'Viral genome' named entity 'global pandemic' named entity 'algorithm' named entity 'Fab regions' named entity 'V-2' named entity 'SARS-CoV-2' named entity 'Viral antigens' named entity 'algorithm' named entity 'mAbs' named entity 'RCSB' named entity 'binding site' named entity 'RCSB' named entity 'spike proteins' named entity 'V-D-J' named entity 'infection' named entity 'V-D-J' named entity 'COVID-19 pandemic' named entity 'monoclonal antibodies' named entity 'I-TASSER' named entity 'antigens' named entity 'Spike protein' named entity 'protein structure' named entity 'predict protein structure'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software